Group 1 - The core viewpoint of the news is that Aoxing Life Science Technology has shown significant stock performance, with a recent increase of 38.46% and a year-to-date increase of 36.84%, outperforming the Hang Seng Index [1] - Aoxing Life Science Technology reported total revenue of 1.5 billion yuan for the year ending December 31, 2024, a decrease of 14.93% year-on-year, while net profit attributable to shareholders was 16.08 million yuan, an increase of 114.17% [1] - The company's gross margin stands at 20.08%, and its debt-to-asset ratio is 61.92% [1] Group 2 - Aoxing Life Science Technology is a technology-based pharmaceutical engineering solution provider operating in over 50 countries, collaborating with leading pharmaceutical companies to enhance human health [2] - The company employs over 1,600 staff globally, providing technology-backed pharmaceutical engineering solutions and ensuring drug safety and efficacy [2] - Aoxing has expertise in various fields, including clean utility engineering, pharmaceutical automation, and biopharmaceutical technology, supported by a professional team and high-quality manufacturing capabilities [2]
奥星生命科技（06118.HK）7月22日收盘上涨38.46%，成交584.6万港元